Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary


Syndax Pharmaceuticals is owned by 61.46% institutional investors, 1.84% insiders, and 36.70% retail investors. Kynam capital management, lp is the largest institutional shareholder, holding 9.87% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals61.46%1.84%36.70%
SectorHealthcare Stocks 232.20%10.74%-142.94%
IndustryBiotech Stocks 382.11%10.55%-292.66%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Kynam capital management, lp8.52M9.87%$131.08M
Blackrock funding, inc. /de8.24M9.51%$173.10M
Blackrock7.91M9.28%$162.33M
Vanguard group6.23M7.19%$130.90M
Goldman sachs group5.70M6.58%$119.66M
Point72 asset management4.26M4.93%$65.46M
State street3.85M4.46%$59.29M
Eversept partners, lp3.47M4.02%$53.34M
Adage capital partners gp3.31M3.84%$50.95M
Kingdon capital management2.50M2.90%$38.46M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp8.52M9.76%$131.08M
Aisling capital management lp1.32M5.78%$27.67M
Lion point capital, lp55.00K4.81%$846.17K
Kingdon capital management2.50M4.77%$38.46M
Catalio capital management, lp1.61M4.59%$24.84M
Stempoint capital lp1.37M4.21%$21.02M
Knott david m jr415.00K4.04%$8.72M
Eversept partners, lp3.47M3.68%$53.34M
Bioimpact capital1.38M3.46%$21.16M
Prosight management, lp665.00K2.89%$13.97M

Top Buyers

HolderShares% AssetsChange
Point72 asset management4.26M0.11%2.13M
Adage capital partners gp3.31M0.08%1.88M
Bioimpact capital1.38M3.46%1.38M
Vanguard group6.23M0.00%1.09M
Ensign peak advisors1.60M0.06%789.48K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---2.27M
Orbimed advisors---1.93M
Bvf inc/il---1.88M
Assenagon asset management41.74K0.00%-1.74M
Balyasny asset management126.14K0.00%-1.69M

New Positions

HolderShares% AssetsChangeValue
Bioimpact capital1.38M3.46%1.38M$21.16M
Apis capital advisors638.00K2.17%638.00K$9.82M
Ikarian capital333.73K0.52%333.73K$5.13M
Canada pension plan investment board229.60K0.00%229.60K$3.53M
Velan capital investment management lp130.00K1.88%130.00K$2.00M

Sold Out

HolderChange
Tfc financial management-1.00
Nelson, van denburg & campbell wealth management group-13.00
Riggs asset managment-26.00
Svb wealth-27.00
Stephens consulting-30.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025166-32.52%53,238,549-47.45%610.45%78-39.06%46-34.29%
Sep 30, 20252385.78%101,267,9708.78%1171.01%1236.03%6913.11%
Jun 30, 2025232-101,730,1911.68%1170.86%116-3.33%651.56%
Mar 31, 20252332.19%100,944,7752.97%1170.90%119-7.03%6510.17%
Dec 31, 2024216-5.68%91,955,1243.35%1070.99%119-4.03%58-1.69%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv2.99M3.50%-
State Street® SPDR® S&P® Biotech ETF2.79M3.20%-14.94K
Vanguard Total Stock Mkt Idx Inv2.73M3.12%9.46K
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
iShares Russell 2000 ETF2.05M2.34%937.29K
SPDR® S&P Biotech ETF1.54M1.78%3.43K
Hood River Small-Cap Growth Instl1.21M1.39%1.21M
Franklin Biotechnology Discv A(acc)USD1.02M1.16%-
Eventide Healthcare & Life Sciences I988.43K1.13%-425.65K
Vanguard Institutional Extnd Mkt Idx Tr940.39K1.08%-878.00

Recent Insider Transactions


DateNameRoleActivityValue
Feb 09, 2026Metzger Michael A Chief Executive OfficerSell$360.82K
Feb 09, 2026Goldan Keith A. Chief Financial OfficerSell$71.71K
Feb 06, 2026Metzger Michael A Chief Executive OfficerSell$152.84K
Feb 06, 2026Goldan Keith A. Chief Financial OfficerSell$42.93K
Sep 08, 2025Metzger Michael A Chief Executive OfficerSell$2.58M

Insider Transactions Trends


DateBuySell
2026 Q1-4
2025 Q4--
2025 Q3-6
2025 Q24-
2025 Q1-4

SNDX Ownership FAQ


Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 61.46%, followed by 1.84% insiders and 36.70% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 382.11%, which Syndax Pharmaceuticals falls below.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Kynam capital management, lp (8.52M shares, 9.87%), Blackrock funding, inc. /de (8.24M shares, 9.51%), and Blackrock (7.91M shares, 9.28%). Together, they hold 28.66% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.76% of its assets in 8.52M Syndax Pharmaceuticals shares, valued at 131.08M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.50% of its total shares outstanding invested in 2.99M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools